IMAdult & adolescent≥16 yr 3 primary doses at 0, 1, 6 mth (standard schedule) or 0, 7, 21 days followed by 4th dose at 12 mth (rapid schedule). Childn & adolescent 1-15 yr 2 primary doses at 0, 6-12 mth. Booster dose General guidelines can be drawn from experience w/ monovalent vaccines.
Anaphylactic reactions. Not to be inj intravascularly. Not for prevention against infection caused by other agents eg, hepatitis C, E & other pathogens infecting the liver. Not recommended for post-exposure prophylaxis (eg, needle-stick injury). Postpone vaccination in patients w/ acute severe febrile illness. Syncope. Haemodialysis or immunocompromised patients. Pregnancy & lactation.
Sign Out
 (pre-filled syringe) 1 mL2a4afbd3-7514-457a-8841-9faa000980f3.GIF)
